Scholars Central

Conference abstractPublished 29 Oct 2012

Radio protective properties of flaxseed and its lignan component-usefulness in ameliorating radiation pneumonopathy

Authors: Melpo Christofidou-Solomidou

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

U sefulness of dietary supplements with potent antioxidant, anti-inflammatory and anti-carcinogenic properties are gaining increasing popularity. Dietary polyphenols such as curcumin, resveratrol, green tea catechins, and flaxseed lignans are currently tested in pre-clinical and clinical studies in the US and worldwide. Treatment of devastating lung conditions like cystic fibrosis, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), radiation pneumonopathy, asthma and cancer is limited by adverse side effects of available treatment drugs. Nutritional supplementation of naturally occurring agents or their more potent synthetic counterparts is evaluated as adjuvant therapy to existing treatment regimens. A better understanding of their use, mechanism of action and effects will ultimately benefit patient care. Flaxseed (FS) and its lignan component (FLC) have known antioxidant properties. Their usefulness in thoracic X-ray radiation (XRT)-induced pneumonopathy was evaluated. We fed mice either FS-, FLC-supplemented or isocaloric control diets for 2-3 weeks prior to a single fraction (13.5Gy) of thoracic radiation. Lungs were evaluated at variable times up to 4 months for inflammation, oxidative lung injury and fibrosis. Oxidative lung damage shown by malondialdehyde (MDA) was significantly decreased post XRT by FS and FLC. Lung fibrosis, as evaluated by lung hydroxyl-proline content and confirmed by histology, was also decreased while mouse survival rates improved. Importantly, neither FS nor FLC protected lung tumors from responding to radiation treatment. Dietary FS or FLC are protective against radiation-induced lung disease and may be useful, and safe as adjuvant therapy in lung cancer treatmen

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Pulmonary & Respiratory Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPulmonary & Respiratory Medicine
  • SubjectPulmonology & Respiratory
  • BylineArticles whose byline prints “Melpo Christofidou-Solomidou”